ASH airing a further reminder of argenx' 'pipeline in a product'

12 December 2022

Autoimmune diseases specialist argenx (Nasdaq: ARGX) has previously referred to Vyvgart (efgartigimod alfa-fcab), an antibody fragment that binds to the neonatal Fc receptor (FcRn), as a ‘pipeline in a product’.

The Belgo-Dutch company had a further chance to demonstrate this with a presentation in the plenary session at the American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans over the weekend.

This presentation was on data from argenx’ Phase III ADVANCE study, the first of two registrational trials evaluating the efficacy, safety and tolerability of Vyvgart for the treatment of adults with primary ITP, this time the intravenous formulation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK